Does the media refer more to SEPN or IPSC?

In the previous week, Septerna and Septerna both had 2 articles in the media. Century Therapeutics' average media sentiment score of 1.47 beat Septerna's score of 0.37 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IPSC or HROW?

In the previous week, Harrow had 5 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for Harrow and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.47 beat Harrow's score of 0.65 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IPSC or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% ArriVent BioPharma N/A -48.98% -45.44%

Does the media prefer IPSC or AVBP?

In the previous week, Century Therapeutics and Century Therapeutics both had 2 articles in the media. Century Therapeutics' average media sentiment score of 1.47 beat ArriVent BioPharma's score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IPSC or MLTX more profitable?

Century Therapeutics' return on equity of -49.89% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media refer more to IPSC or MLTX?

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Century Therapeutics. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.47 beat MoonLake Immunotherapeutics' score of 0.39 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KALV or IPSC more profitable?

Century Therapeutics' return on equity of -49.89% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets KalVista Pharmaceuticals N/A -341.44% -111.94% Century Therapeutics N/A -49.89% -37.42%

Century Therapeutics (IPSC) Competitors

$2.19 -0.06 (-2.67%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$2.26 +0.07 (+3.15%)

As of 04:03 AM Eastern

Compare

IPSC vs. SEPN, HROW, AVBP, MLTX, and KALV

Should you buy Century Therapeutics stock or one of its competitors? MarketBeat compares Century Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Century Therapeutics include Septerna (SEPN), Harrow (HROW), ArriVent BioPharma (AVBP), MoonLake Immunotherapeutics (MLTX), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

How does Century Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

50.2% of Century Therapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Septerna and Septerna both had 2 articles in the media. Century Therapeutics' average media sentiment score of 1.47 beat Septerna's score of 0.37 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna presently has a consensus price target of $45.89, suggesting a potential upside of 42.47%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 116.89%. Given Century Therapeutics' higher probable upside, analysts clearly believe Century Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Century Therapeutics	N/A	-49.89%	-37.42%

Septerna has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Century Therapeutics has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	31.60	-$48.88M	-$0.81	N/A
Century Therapeutics	$109.16M	3.62	-$9.58M	-$1.14	N/A

Summary

Septerna beats Century Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to Harrow?

Century Therapeutics (NASDAQ:IPSC) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Century Therapeutics presently has a consensus target price of $4.75, indicating a potential upside of 116.89%. Harrow has a consensus target price of $69.43, indicating a potential upside of 56.19%. Given Century Therapeutics' higher possible upside, equities research analysts clearly believe Century Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Century Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Harrow has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Harrow had 5 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for Harrow and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.47 beat Harrow's score of 0.65 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Century Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Harrow	-5.57%	19.59%	2.26%

Harrow has higher revenue and earnings than Century Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.62	-$9.58M	-$1.14	N/A
Harrow	$272.30M	6.09	-$5.14M	-$0.41	N/A

Summary

Harrow beats Century Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to ArriVent BioPharma?

Century Therapeutics (NASDAQ:IPSC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Century Therapeutics and Century Therapeutics both had 2 articles in the media. Century Therapeutics' average media sentiment score of 1.47 beat ArriVent BioPharma's score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

ArriVent BioPharma's return on equity of -48.98% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Century Therapeutics presently has a consensus price target of $4.75, suggesting a potential upside of 116.89%. ArriVent BioPharma has a consensus price target of $44.83, suggesting a potential upside of 58.87%. Given Century Therapeutics' higher possible upside, research analysts plainly believe Century Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Century Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.62	-$9.58M	-$1.14	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Summary

Century Therapeutics beats ArriVent BioPharma on 9 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

Century Therapeutics (NASDAQ:IPSC) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Century Therapeutics. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.47 beat MoonLake Immunotherapeutics' score of 0.39 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 116.89%. MoonLake Immunotherapeutics has a consensus price target of $24.21, indicating a potential upside of 27.11%. Given Century Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Century Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Century Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Century Therapeutics' return on equity of -49.89% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Century Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.62	-$9.58M	-$1.14	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Summary

Century Therapeutics beats MoonLake Immunotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Century Therapeutics had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 2 mentions for Century Therapeutics and 0 mentions for KalVista Pharmaceuticals. Century Therapeutics' average media sentiment score of 1.47 beat KalVista Pharmaceuticals' score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
KalVista Pharmaceuticals	Neutral
Century Therapeutics	Positive

50.2% of Century Therapeutics shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Century Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A
Century Therapeutics	$109.16M	3.62	-$9.58M	-$1.14	N/A

Century Therapeutics' return on equity of -49.89% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Century Therapeutics	N/A	-49.89%	-37.42%

KalVista Pharmaceuticals has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

KalVista Pharmaceuticals currently has a consensus target price of $33.25, indicating a potential upside of 23.15%. Century Therapeutics has a consensus target price of $4.75, indicating a potential upside of 116.89%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Century Therapeutics beats KalVista Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$405.80M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-1.92	20.20	27.07	23.94
Price / Sales	3.62	340.68	512.71	90.33
Price / Cash	169.17	27.11	26.68	47.25
Price / Book	1.20	4.20	10.63	6.14
Net Income	-$9.58M	$65.94M	$3.60B	$331.74M
7 Day Performance	2.82%	-3.05%	-1.24%	-1.82%
1 Month Performance	-4.37%	-1.30%	1.09%	-1.45%
1 Year Performance	280.87%	15.22%	23.66%	16.32%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	2.0033 of 5 stars	$2.19 -2.7%	$4.75 +116.9%	+277.1%	$405.80M	$109.16M	N/A	170	Positive News
SEPN Septerna	2.1661 of 5 stars	$34.51 +0.4%	$45.89 +33.0%	+156.7%	$1.56B	$45.95M	N/A	N/A
HROW Harrow	4.3265 of 5 stars	$41.41 -1.0%	$69.43 +67.7%	+23.9%	$1.54B	$272.30M	N/A	180	News Coverage
AVBP ArriVent BioPharma	2.0663 of 5 stars	$32.51 -3.4%	$44.83 +37.9%	+28.0%	$1.51B	N/A	N/A	40
MLTX MoonLake Immunotherapeutics	2.9558 of 5 stars	$20.12 -1.4%	$24.21 +20.3%	-64.1%	$1.48B	N/A	N/A	2	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. SEPN, HROW, AVBP, MLTX, and KALV

How does Century Therapeutics compare to Septerna?

Summary

How does Century Therapeutics compare to Harrow?

Summary

How does Century Therapeutics compare to ArriVent BioPharma?

Summary

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Century Therapeutics compare to KalVista Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. SEPN, HROW, AVBP, MLTX, and KALV

How does Century Therapeutics compare to Septerna?

Do institutionals & insiders have more ownership in SEPN or IPSC?

Does the media refer more to SEPN or IPSC?

Do analysts rate SEPN or IPSC?

Is SEPN or IPSC more profitable?

Which has more risk & volatility, SEPN or IPSC?

Which has stronger valuation and earnings, SEPN or IPSC?

Summary

How does Century Therapeutics compare to Harrow?

Do analysts rate IPSC or HROW?

Which has more risk and volatility, IPSC or HROW?

Do institutionals and insiders have more ownership in IPSC or HROW?

Does the media prefer IPSC or HROW?

Is IPSC or HROW more profitable?

Which has preferable earnings & valuation, IPSC or HROW?

Summary

How does Century Therapeutics compare to ArriVent BioPharma?

Does the media prefer IPSC or AVBP?

Which has more risk and volatility, IPSC or AVBP?

Is IPSC or AVBP more profitable?

Do analysts rate IPSC or AVBP?

Do institutionals and insiders hold more shares of IPSC or AVBP?

Which has better earnings & valuation, IPSC or AVBP?

Summary

How does Century Therapeutics compare to MoonLake Immunotherapeutics?

Does the media refer more to IPSC or MLTX?

Do analysts prefer IPSC or MLTX?

Do insiders & institutionals believe in IPSC or MLTX?

Which has more risk and volatility, IPSC or MLTX?

Is IPSC or MLTX more profitable?

Which has better valuation & earnings, IPSC or MLTX?

Summary

How does Century Therapeutics compare to KalVista Pharmaceuticals?

Does the media refer more to KALV or IPSC?

Do insiders and institutionals hold more shares of KALV or IPSC?

Which has higher earnings & valuation, KALV or IPSC?

Is KALV or IPSC more profitable?

Which has more volatility & risk, KALV or IPSC?

Do analysts recommend KALV or IPSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools